Low-and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: A prospective study

Nephrology Dialysis Transplantation

Volumn 28, Issue 1, 2013, Pages 137-146

  Irazabal, Maria V ^a   Eirin, Alfonso ^a   Lieske, John ^a   Beck, Laurence H ^b   Sethi, Sanjeev ^c   Borland, Timothy M ^c   Dillon, John J ^a   Nachman, Patrick H ^d   Nasr, Samih H ^c   Cornell, Lynn D ^c   Leung, Nelson ^a   Cattran, Daniel C ^e   Fervenza, Fernando C ^a  

^a Mayo Clinic College of Medicine   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

membranous nephropathy; rituximab; urinary proteins

Indexed keywords

ALBUMIN; ALPHA 1 MICROGLOBULIN; BIOLOGICAL MARKER; HIGH MOLECULAR WEIGHT URINARY PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOW MOLECULAR WEIGHT URINARY PROTEIN; PHOSPHOLIPASE A2 RECEPTOR; PHOSPHOLIPASE A2 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; RETINOL BINDING PROTEIN; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; MALE; MEMBRANOUS GLOMERULONEPHRITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN URINE LEVEL; PROTEINURIA; QUANTITATIVE ANALYSIS; RELAPSE; REMISSION; TREATMENT DURATION; URINARY EXCRETION;

ADULT; ALPHA-GLOBULINS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOMARKERS, PHARMACOLOGICAL; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA; RETINOL-BINDING PROTEINS; TREATMENT OUTCOME;

EID: 84872254697     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs379     Document Type: Article

References (37)

1. Medawar W, Green A, Campbell E et al. Clinical and histopathologic findings in adults with the nephrotic syndrome. Ir J Med Sci 1990; 159: 137-140.
2. Ruggenenti P, Chiurchiu C, Brusegan Vet al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 2003; 14: 1851-1857.
3. Cattran DC. Membranous nephropathy: quo vadis? [comment]. Kidney Int 2002; 61: 349-350.
4. Wagoner RD, Stanson AW, Holley KE et al. Renal vein thrombosis in idiopathic membranous glomerulopathy and nephrotic syndrome: incidence and significance. Kidney Int 1983; 23: 368-374.
5. Ordonez JD, Hiatt RA, Killebrew EJ et al. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993; 44: 638-642.
6. Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis 1994; 23: 331-346.
7. Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol 2008; 3: 905-919.
8. Polanco N, Gutierrez E, Covarsi A et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010; 21: 697-704.
9. Cattran DC, Pei Y, Greenwood C. Predicting progression in membranous glomerulonephritis. Nephrol Dial Transplant 1992; 7(Suppl 1): 48-52.
10. Pei Y, Cattran D, Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 1992; 42: 960-966.
11. Cattran DC, Pei Y, Greenwood CM et al. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 1997; 51: 901-907.
12. Reichert LJ, Koene RA, Wetzels JF. Urinary excretion of beta 2-microglobulin predicts renal outcome in patients with idiopathic membranous nephropathy. J Am Soc Nephrol 1995; 6: 1666-1669.
13. Reichert LJ, Koene RA, Wetzels JF. Urinary IgG excretion as a prognostic factor in idiopathic membranous nephropathy. Clin Nephrol 1997; 48: 79-84.
14. Bazzi C, Petrini C, Rizza V et al. Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant 2002; 17: 1890-1896.
15. Branten AJ, du Buf-Vereijken PW, Klasen IS et al. Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol 2005; 16: 169-174.
16. Hofstra JM, Deegens JK, Willems HL et al. Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy. Nephrol Dial Transplant 2008; 23: 2546-2551.
17. Bazzi C, Petrini C, Rizza V et al. Urinary excretion of IgG and alpha(1)-microglobulin predicts clinical course better than extent of proteinuria in membranous nephropathy. Am J Kidney Dis 2001; 38: 240-248.
18. Bakoush O, Torffvit O, Rippe B et al. High proteinuria selectivity index based upon IgM is a strong predictor of poor renal survival in glomerular diseases. Nephrol Dial Transplant 2001; 16: 1357-1363.
19. Bakoush O, Torffvit O, Rippe B et al. Renal function in proteinuric glomerular diseases correlates to the changes in urine IgM excretion but not to the changes in the degree of albuminuria. Clin Nephrol 2003; 59: 345-352.
20. Deegens JK, Wetzels JF. Fractional excretion of high-and lowmolecular weight proteins and outcome in primary focal segmental glomerulosclerosis. Clin Nephrol 2007; 68: 201-208.
21. McQuarrie EP, Shakerdi L, Jardine AG et al. Fractional excretions of albumin and IgG are the best predictors of progression in primary glomerulonephritis. Nephrol Dial Transplant 2011; 26: 1563-1569.
22. Bazzi C, Petrini C, Rizza V et al. Fractional excretion of IgG predicts renal outcome and response to therapy in primary focal segmental glomerulosclerosis: a pilot study. Am J Kidney Dis 2003; 41: 328-335.
23. du Buf-Vereijken PW, Wetzels JF. Treatment-related changes in urinary excretion of high and low molecular weight proteins in patients with idiopathic membranous nephropathy and renal insufficiency. Nephrol Dial Transplant 2006; 21: 389-396.
24. Bazzi C, Rizza V, Paparella M et al. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy. J Nephrol 2009; 22: 387-396.
25. Fervenza FC, Abraham RS, Erickson SB et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 2010; 5: 2188-2198.
26. Beck LH, Jr, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11-21.
27. Beck LH, Jr, Fervenza FC, Beck DM et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011; 22: 1543-1550.
28. Bazzi C, D'Amico G. The urinary excretion of IgG and alpha1-microglobulin predicts renal outcome and identifies patients deserving treatment in membranous nephropathy. Kidney Int 2002; 61: 2276.
29. Fervenza FC, Cosio FG, Erickson SB et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008; 73: 117-125.
30. Ponticelli C, Zucchelli P, Passerini P et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995; 48: 1600-1604.
31. D'Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int 2003; 63: 809-825.
32. Blouch K, Deen WM, Fauvel JP et al. Molecular configuration and glomerular size selectivity in healthy and nephrotic humans. Am J Physiol 1997; 273: F430-F437.
33. Ruggenenti P, Chiurchiu C, Abbate M et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol 2006; 1: 738-748.
34. Troyanov S, Roasio L, Pandes M et al. Renal pathology in idiopathic membranous nephropathy: a new perspective. Kidney Int 2006; 69: 1641-1648.
35. Fornoni A, Sageshima J, Wei C et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011; 3: 85ra46.
36. Perosa F, Favoino E, Caragnano MA et al. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 2006; 107: 1070-1077.
37. Faul C, Donnelly M, Merscher-Gomez S et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008; 14: 931-938.